2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Carcinoma, Hepatocellular in 49 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) and sorafenib resistance remain enigmatic." | 7.83 | Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. ( Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF, 2016) |
| "The purpose of this study was to investigate the effect of bufalin on the anti-proliferative activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and Hep G-2 and to determine the relevant molecular mechanism." | 7.78 | Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. ( Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY, 2012) |
| "Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) and sorafenib resistance remain enigmatic." | 3.83 | Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. ( Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF, 2016) |
| "Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but its use is hampered by the occurrence of drug resistance." | 3.79 | Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. ( Dekervel, J; Nevens, F; Van Cutsem, E; van Malenstein, H; van Pelt, J; Verslype, C; Windmolders, P, 2013) |
| "The purpose of this study was to investigate the effect of bufalin on the anti-proliferative activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and Hep G-2 and to determine the relevant molecular mechanism." | 3.78 | Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. ( Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY, 2012) |
| "Hepatocellular carcinoma has extremely poor prognosis." | 1.48 | Autophagy‑mediated adaptation of hepatocellular carcinoma cells to hypoxia‑mimicking conditions constitutes an attractive therapeutic target. ( Endo, H; Ito, K; Nezu, T; Okada, C; Owada, S; Shida, Y; Tatemichi, M, 2018) |
| "Drug treatments for hepatocellular carcinoma (HCC) often fail because of multidrug resistance (MDR)." | 1.46 | USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. ( Dai, H; Li, J; Ling, S; Liu, J; Lu, D; Shan, Q; Song, P; Wen, X; Xie, H; Xu, X; Zheng, S; Zhou, L, 2017) |
| "Cancer stem cells in liver cancer are thought to be responsible for tumor recurrence and metastasis." | 1.46 | Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling. ( Fu, Z; Jia, J; Li, JP; Lu, R; Wang, L; Wang, S; Xu, HX; Xu, Q; Yao, Z; Zhu, ZF, 2017) |
| "Heptocelluar carcinoma (HCC) is insensitive to chemotherapy due to limited bioavailability and acquired drug resistance." | 1.43 | Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT. ( Chen, L; Chen, XP; Li, GZ; Liang, HF; Zhang, BX; Zhou, HH, 2016) |
| "To investigate the role of miR-20a in hepatocellular carcinoma (HCC) cell radioresistance, which may reveal potential strategies to improve treatment." | 1.42 | MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. ( Chen, L; Ding, Y; Li, Q; Liu, T; Peng, S; Sun, Q; Wang, R; Wang, W; Yang, H; Zhang, Y; Zheng, L, 2015) |
| "Human hepatocellular carcinoma (HCC) cell lines SMMC7721 and Huh7 were used." | 1.39 | Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. ( Ding, X; Dong, S; Gao, J; Ke, S; Kong, F; Kong, J; Sun, W; Wang, S; Zheng, L, 2013) |
| "In Mahlavu human hepatoma cells Akt was constitutively activated, as demonstrated by its Ser473 phosphorylation, downstream hyperphosphorylation of BAD on Ser136, and by a specific cell-free kinase assay." | 1.37 | Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. ( Buontempo, F; Capitani, S; Cetin-Atalay, R; Ersahin, T; Etro, D; Missiroli, S; Neri, ML; Ozturk, M; Senturk, S, 2011) |
| "We investigated this in vitro by treating hepatocellular carcinoma cells under 1." | 1.35 | PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells. ( Fu, Y; Liao, J; Liu, M; Luo, M; Tian, D; Wang, B; Xia, L; Yan, W; Zhu, Q, 2009) |
| "Two highly metastatic liver cancer cell lines showed high Akt activity and formed many colonies in soft agar, whereas three nonmetastatic cell lines showed less Akt activity and formed fewer colonies." | 1.31 | Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. ( Fujita, N; Hirohashi, S; Nakanishi, K; Sakamoto, M; Takamura, M; Todo, S; Tsuruo, T; Yasuda, J, 2002) |
| "In HTC hepatoma cells, increases in volume are coupled to membrane ion permeability through a pathway involving (i) ATP efflux, (ii) autocrine stimulation of P2 receptors, and (iii) increases in anion permeability and Cl- efflux, contributing to recovery of volume toward basal values." | 1.30 | Phosphatidylinositol 3-kinase contributes to cell volume regulation through effects on ATP release. ( Feranchak, AP; Fitz, JG; Roman, RM; Schwiebert, EM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.08) | 18.2507 |
| 2000's | 17 (34.69) | 29.6817 |
| 2010's | 30 (61.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Y | 1 |
| Wu, D | 1 |
| Wang, M | 1 |
| Li, W | 1 |
| Ling, S | 1 |
| Li, J | 2 |
| Shan, Q | 1 |
| Dai, H | 1 |
| Lu, D | 1 |
| Wen, X | 1 |
| Song, P | 1 |
| Xie, H | 1 |
| Zhou, L | 2 |
| Liu, J | 1 |
| Xu, X | 1 |
| Zheng, S | 1 |
| Bai, PS | 1 |
| Xia, N | 1 |
| Sun, H | 1 |
| Kong, Y | 1 |
| Owada, S | 1 |
| Endo, H | 1 |
| Shida, Y | 1 |
| Okada, C | 1 |
| Ito, K | 1 |
| Nezu, T | 1 |
| Tatemichi, M | 1 |
| Xu, Y | 1 |
| Zhou, W | 1 |
| Ji, Y | 1 |
| Shen, J | 2 |
| Zhu, X | 1 |
| Yu, H | 1 |
| Guo, J | 1 |
| Pang, Z | 1 |
| Wei, W | 1 |
| Zhou, LJ | 1 |
| Mo, YB | 1 |
| Bu, X | 1 |
| Wang, JJ | 1 |
| Bai, J | 1 |
| Zhang, JW | 1 |
| Cheng, AB | 1 |
| Ma, JH | 1 |
| Wang, YW | 1 |
| Xie, YX | 1 |
| Zhang, X | 2 |
| Shao, J | 1 |
| Li, X | 2 |
| Cui, L | 1 |
| Tan, Z | 1 |
| Ye, G | 1 |
| Qin, Y | 2 |
| Wang, S | 3 |
| Pan, D | 1 |
| Xu, S | 1 |
| Wu, C | 1 |
| Wang, X | 1 |
| Wang, J | 2 |
| Ye, H | 1 |
| Shen, H | 1 |
| Wu, J | 1 |
| Meng, J | 1 |
| Du, Y | 1 |
| Huang, Y | 2 |
| Jin, Y | 1 |
| Zhang, J | 1 |
| Wang, B | 2 |
| Zhang, Y | 3 |
| Sun, M | 1 |
| Tang, J | 1 |
| Ma, J | 3 |
| Xie, SL | 1 |
| Geng, YJ | 1 |
| Jin, S | 1 |
| Wang, GY | 1 |
| Lv, GY | 1 |
| Baba, A | 1 |
| Shimizu, M | 1 |
| Ohno, T | 1 |
| Shirakami, Y | 1 |
| Kubota, M | 1 |
| Kochi, T | 1 |
| Terakura, D | 1 |
| Tsurumi, H | 1 |
| Moriwaki, H | 1 |
| Dong, S | 1 |
| Kong, J | 2 |
| Kong, F | 1 |
| Gao, J | 1 |
| Ke, S | 1 |
| Ding, X | 1 |
| Sun, W | 1 |
| Zheng, L | 2 |
| Kunter, I | 1 |
| Erdal, E | 1 |
| Nart, D | 1 |
| Yilmaz, F | 1 |
| Karademir, S | 1 |
| Sagol, O | 1 |
| Atabey, N | 1 |
| Ding, Y | 1 |
| Li, Q | 1 |
| Wang, R | 1 |
| Liu, T | 1 |
| Sun, Q | 1 |
| Yang, H | 1 |
| Peng, S | 1 |
| Wang, W | 1 |
| Chen, L | 2 |
| García-Álvaro, M | 1 |
| Addante, A | 1 |
| Roncero, C | 1 |
| Fernández, M | 1 |
| Fabregat, I | 1 |
| Sánchez, A | 1 |
| Herrera, B | 1 |
| Zhang, PF | 1 |
| Li, KS | 1 |
| Shen, YH | 1 |
| Gao, PT | 1 |
| Dong, ZR | 1 |
| Cai, JB | 1 |
| Zhang, C | 1 |
| Huang, XY | 1 |
| Tian, MX | 1 |
| Hu, ZQ | 1 |
| Gao, DM | 1 |
| Fan, J | 2 |
| Ke, AW | 1 |
| Shi, GM | 1 |
| Zhou, HH | 1 |
| Liang, HF | 1 |
| Li, GZ | 1 |
| Zhang, BX | 1 |
| Chen, XP | 1 |
| Yuan, M | 1 |
| Guo, H | 1 |
| Sui, C | 1 |
| Khan, YH | 1 |
| Ye, L | 1 |
| Xie, F | 1 |
| Wang, H | 1 |
| Yuan, L | 1 |
| Ye, J | 1 |
| Peng, YC | 1 |
| Peng, NF | 1 |
| Xie, ZB | 1 |
| Lu, SD | 1 |
| Zhong, JH | 1 |
| Pang, YB | 1 |
| Zhu, SL | 1 |
| You, XM | 1 |
| Li, LQ | 1 |
| Xu, Q | 1 |
| Xu, HX | 1 |
| Li, JP | 1 |
| Fu, Z | 1 |
| Jia, J | 1 |
| Wang, L | 2 |
| Zhu, ZF | 1 |
| Lu, R | 1 |
| Yao, Z | 1 |
| Chen, KF | 1 |
| Yeh, PY | 1 |
| Hsu, C | 1 |
| Hsu, CH | 1 |
| Lu, YS | 1 |
| Hsieh, HP | 1 |
| Chen, PJ | 1 |
| Cheng, AL | 1 |
| Yan, W | 1 |
| Fu, Y | 1 |
| Tian, D | 1 |
| Liao, J | 1 |
| Liu, M | 2 |
| Xia, L | 1 |
| Zhu, Q | 1 |
| Luo, M | 1 |
| He, S | 1 |
| Lu, M | 1 |
| Xue, W | 1 |
| Wang, Y | 1 |
| Zhao, Y | 1 |
| Gao, S | 1 |
| Ke, Q | 1 |
| Liu, Y | 2 |
| Li, P | 1 |
| Cui, X | 1 |
| Cheng, C | 1 |
| Shen, A | 1 |
| Mei, C | 1 |
| Sun, L | 1 |
| Yang, Y | 1 |
| Cai, X | 1 |
| Yao, W | 1 |
| Wang, C | 1 |
| Li, Z | 1 |
| Shi, Y | 2 |
| Qiu, S | 1 |
| Zha, X | 1 |
| Buontempo, F | 1 |
| Ersahin, T | 1 |
| Missiroli, S | 1 |
| Senturk, S | 1 |
| Etro, D | 1 |
| Ozturk, M | 1 |
| Capitani, S | 1 |
| Cetin-Atalay, R | 1 |
| Neri, ML | 1 |
| Lai, JP | 1 |
| Sandhu, DS | 1 |
| Yu, C | 1 |
| Moser, CD | 1 |
| Hu, C | 1 |
| Shire, AM | 1 |
| Aderca, I | 1 |
| Murphy, LM | 1 |
| Adjei, AA | 1 |
| Sanderson, S | 1 |
| Roberts, LR | 1 |
| Yan, DM | 1 |
| Dai, RY | 1 |
| Duan, CY | 1 |
| Chen, SK | 1 |
| Liu, YP | 1 |
| Chen, CN | 1 |
| Li, H | 1 |
| Ning, J | 1 |
| Hong, T | 1 |
| Yang, X | 1 |
| Mei, S | 1 |
| Liu, Z | 1 |
| Liu, HY | 1 |
| Cao, W | 1 |
| Gao, Y | 1 |
| Li, HX | 1 |
| Xu, LT | 1 |
| Wang, P | 1 |
| Xu, LY | 1 |
| Cohen, L | 1 |
| Yang, PY | 1 |
| Gu, K | 1 |
| Meng, ZQ | 1 |
| Jiao, M | 1 |
| Nan, KJ | 1 |
| van Malenstein, H | 1 |
| Dekervel, J | 1 |
| Verslype, C | 1 |
| Van Cutsem, E | 1 |
| Windmolders, P | 1 |
| Nevens, F | 1 |
| van Pelt, J | 1 |
| Huo, X | 1 |
| Zhang, Q | 1 |
| Liu, AM | 1 |
| Tang, C | 1 |
| Gong, Y | 1 |
| Bian, J | 1 |
| Luk, JM | 1 |
| Xu, Z | 1 |
| Chen, J | 1 |
| Mottet, D | 1 |
| Dumont, V | 1 |
| Deccache, Y | 1 |
| Demazy, C | 1 |
| Ninane, N | 1 |
| Raes, M | 1 |
| Michiels, C | 1 |
| Qi, HL | 1 |
| Guo, P | 1 |
| Zhang, XY | 1 |
| Chen, HL | 2 |
| Hirashima, Y | 1 |
| Tsuruzoe, K | 1 |
| Kodama, S | 1 |
| Igata, M | 1 |
| Toyonaga, T | 1 |
| Ueki, K | 1 |
| Kahn, CR | 1 |
| Araki, E | 1 |
| Keeton, AB | 2 |
| Xu, J | 1 |
| Franklin, JL | 2 |
| Messina, JL | 2 |
| Bortoff, KD | 1 |
| Beurel, E | 1 |
| Kornprobst, M | 1 |
| Blivet-Van Eggelpoël, MJ | 1 |
| Cadoret, A | 1 |
| Capeau, J | 1 |
| Desbois-Mouthon, C | 1 |
| Qi, XJ | 1 |
| Wildey, GM | 1 |
| Howe, PH | 1 |
| Xue, Y | 1 |
| Bi, F | 1 |
| Zhang, S | 1 |
| Pan, Y | 1 |
| Liu, N | 1 |
| Yao, X | 1 |
| Zheng, Y | 1 |
| Fan, D | 1 |
| Roudier, E | 1 |
| Mistafa, O | 1 |
| Stenius, U | 1 |
| Ishida, H | 1 |
| Li, K | 1 |
| Yi, M | 1 |
| Lemon, SM | 1 |
| Jiang, J | 1 |
| Wei, Y | 1 |
| Liu, D | 1 |
| Zhou, J | 1 |
| Gu, J | 1 |
| Feranchak, AP | 1 |
| Roman, RM | 1 |
| Schwiebert, EM | 1 |
| Fitz, JG | 1 |
| Sipeki, S | 1 |
| Bander, E | 1 |
| Buday, L | 1 |
| Farkas, G | 1 |
| Bácsy, E | 1 |
| Ways, DK | 1 |
| Faragó, A | 1 |
| Guo, HB | 1 |
| Shen, ZH | 1 |
| Huang, CX | 1 |
| Banfi, C | 1 |
| Eriksson, P | 1 |
| Giandomenico, G | 1 |
| Mussoni, L | 1 |
| Sironi, L | 1 |
| Hamsten, A | 1 |
| Tremoli, E | 1 |
| Scassa, ME | 1 |
| Guberman, AS | 1 |
| Varone, CL | 1 |
| Cánepa, ET | 1 |
| Nakanishi, K | 1 |
| Sakamoto, M | 1 |
| Yasuda, J | 1 |
| Takamura, M | 1 |
| Fujita, N | 1 |
| Tsuruo, T | 1 |
| Todo, S | 1 |
| Hirohashi, S | 1 |
49 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
C-Terminus of E1A Binding Protein 1 Stimulates Malignant Phenotype in Human Hepatocellular Carcinoma.
Topics: Aged; Alcohol Oxidoreductases; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement | 2019 |
USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Animals; Apoptosis Regulatory Proteins; | 2017 |
Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Carrier Proteins; Cell Proliferation; Chromones; Cytokines; fas Re | 2017 |
Autophagy‑mediated adaptation of hepatocellular carcinoma cells to hypoxia‑mimicking conditions constitutes an attractive therapeutic target.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Hypoxia; Cell L | 2018 |
Elongator promotes the migration and invasion of hepatocellular carcinoma cell by the phosphorylation of AKT.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Chromones; DNA Damage; Female | 2018 |
Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3β Signaling Pathway in Human Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Chromones; Diterpenes; Female | 2018 |
Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133‑expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway.
Topics: AC133 Antigen; Adult; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferatio | 2019 |
Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Chromones; Glucose; Hep G2 Cells; Humans; La | 2019 |
RACK1 promotes the proliferation, migration and invasion capacity of mouse hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1 signaling pathway.
Topics: Animals; Anthracenes; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; | 2013 |
In vitro regulation of hepatocellular carcinoma cell viability, apoptosis, invasion, and AEG-1 expression by LY294002.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Survival; Chromones; Enzyme Inhi | 2014 |
Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin D1; Cy | 2013 |
Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Chromones; Disease Progress | 2013 |
Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C | 2014 |
MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Humans; Liver Neoplasms; Luciferases; MicroR | 2015 |
BMP9-Induced Survival Effect in Liver Tumor Cells Requires p38MAPK Activation.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Tran | 2015 |
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance | 2016 |
Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; C | 2016 |
Slit2 and Robo1 induce opposing effects on metastasis of hepatocellular carcinoma Sk-hep-1 cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Gene Expression Regulati | 2016 |
[Role of PI3K/AKT signaling pathway in clonogenicity and tumorigenicity of CD90+ stem-like cells of the hepatocellular carcinoma cell line MHCC-97H].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Humans; Liver Neoplasms; Mice; Mice | 2016 |
Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling.
Topics: Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2017 |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, T | 2009 |
PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Chromones; Epithelium; Humans; Liver Neoplasms; Mesoderm; M | 2009 |
Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro.
Topics: Adult; Aged; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Chromones; Cyclin-Dependent K | 2011 |
Transcriptional and post-transcriptional control of DNA methyltransferase 3B is regulated by phosphatidylinositol 3 kinase/Akt pathway in human hepatocellular carcinoma cell lines.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; DNA (Cytosine-5-)-Methyltransferases; DNA Me | 2010 |
Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinoma, Hepatocellular; Cell Li | 2011 |
Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Topics: Apoptosis; bcl-Associated Death Protein; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Ca | 2010 |
[Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress].
Topics: Butadienes; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chromones; Endoplasmic Reticulu | 2010 |
Insulin and insulin signaling play a critical role in fat induction of insulin resistance in mouse.
Topics: Acyl Coenzyme A; Adenosine Diphosphate; Adenosine Triphosphate; Adipose Tissue; Animals; Carcinoma, | 2011 |
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; | 2012 |
Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2012 |
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Topics: Anilides; Antineoplastic Agents; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; | 2013 |
Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Antibiotics, Antineoplastic; Apoptosis; bcl-X Protein; Butadie | 2013 |
Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Chromones; DNA-Binding Proteins; Enzyme Inhibitor | 2003 |
Insulin/protein kinase B signalling pathway upregulates metastasis-related phenotypes and molecules in H7721 human hepatocarcinoma cell line.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Cell Adhesion; Cell Movement; Cells, Cultured; Ch | 2003 |
Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Chromones; Cycloheximide; Depression, Chemical; Enzym | 2003 |
Regulation of Gene33 expression by insulin requires MEK-ERK activation.
Topics: Adaptor Proteins, Signal Transducing; Androstadienes; Animals; Carcinoma, Hepatocellular; Carrier Pr | 2004 |
Blockade of rapid versus prolonged extracellularly regulated kinase 1/2 activation has differential effects on insulin-induced gene expression.
Topics: Activating Transcription Factor 3; Androstadienes; Animals; Carcinoma, Hepatocellular; Cell Line, Tu | 2005 |
GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Caspas | 2005 |
Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function.
Topics: 14-3-3 Proteins; Alkaline Phosphatase; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like | 2006 |
Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation.
Topics: Blotting, Western; Carcinoma, Hepatocellular; cdc42 GTP-Binding Protein; Cell Hypoxia; Cell Line, Tu | 2006 |
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepa | 2006 |
p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Extracellular Signal-Reg | 2007 |
Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and thus sensitize SMMC-7721 human hepatocarcinoma cells to cycloheximide-induced apoptosis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular | 2007 |
Phosphatidylinositol 3-kinase contributes to cell volume regulation through effects on ATP release.
Topics: Adenosine Triphosphate; Androstadienes; Animals; Antibodies; Carcinoma, Hepatocellular; Cell Membran | 1998 |
Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering.
Topics: Carcinoma, Hepatocellular; Cell Movement; Chromones; Cycloheximide; Enzyme Inhibitors; Flavonoids; H | 1999 |
Modulation of the basal activity of phosphatidylinositol-3-kinase/protein kinase B signaling pathway in human hepatocarcinoma cells.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Chromones; DNA, Antisense; Enzyme Activation; Enz | 2000 |
Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway.
Topics: Base Sequence; Carcinoma, Hepatocellular; Chromones; Chromosome Mapping; Enzyme Inhibitors; Humans; | 2001 |
Phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase signaling pathways are required for the regulation of 5-aminolevulinate synthase gene expression by insulin.
Topics: 5-Aminolevulinate Synthetase; Androstadienes; Animals; Carcinoma, Hepatocellular; Cells, Cultured; C | 2001 |
Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Division; Chromones; Enzyme Activation; Enzy | 2002 |